Taysha Gene Therapies Presents New Preclinical In-Vitro Data On TSHA-102 In Rett Syndrome Supporting miRARE Regulation Of MECP2 Expression At The European Society Of Gene & Cell Therapy 30th Annual Congress
Portfolio Pulse from Benzinga Newsdesk
Taysha Gene Therapies has presented new preclinical in-vitro data on TSHA-102 in Rett Syndrome at the European Society of Gene & Cell Therapy 30th Annual Congress. The data showed that the miRARE control element downregulates MECP2 transgene and protein expression in response to cellular levels of MeCP2 in cell culture models. Clinical data from two adult patients dosed with TSHA-102 will be reported in mid-November, and the first pediatric Rett syndrome patient is expected to be dosed in Q1 2024.
October 24, 2023 | 12:10 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Taysha Gene Therapies' new preclinical data on TSHA-102 in Rett Syndrome shows promising results. Clinical data from two adult patients will be reported in mid-November, and the first pediatric patient is expected to be dosed in Q1 2024.
The positive preclinical data on TSHA-102 in Rett Syndrome is likely to boost investor confidence in Taysha Gene Therapies. The upcoming release of clinical data from two adult patients in mid-November and the dosing of the first pediatric patient in Q1 2024 could further increase the company's stock value.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100